ES2527173T3 - Células de fucosilación deficiente - Google Patents
Células de fucosilación deficiente Download PDFInfo
- Publication number
- ES2527173T3 ES2527173T3 ES10721096.5T ES10721096T ES2527173T3 ES 2527173 T3 ES2527173 T3 ES 2527173T3 ES 10721096 T ES10721096 T ES 10721096T ES 2527173 T3 ES2527173 T3 ES 2527173T3
- Authority
- ES
- Spain
- Prior art keywords
- poor
- cell
- glycoprotein
- fucosylation
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18340009P | 2009-06-02 | 2009-06-02 | |
| US183400P | 2009-06-02 | ||
| US34885810P | 2010-05-27 | 2010-05-27 | |
| US348858P | 2010-05-27 | ||
| PCT/US2010/036914 WO2010141478A1 (en) | 2009-06-02 | 2010-06-01 | Fucosylation-deficient cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2527173T3 true ES2527173T3 (es) | 2015-01-21 |
Family
ID=42338231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10721096.5T Active ES2527173T3 (es) | 2009-06-02 | 2010-06-01 | Células de fucosilación deficiente |
| ES14179885.0T Active ES2661074T3 (es) | 2009-06-02 | 2010-06-01 | Células deficientes de fucosilación |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14179885.0T Active ES2661074T3 (es) | 2009-06-02 | 2010-06-01 | Células deficientes de fucosilación |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8409838B2 (enExample) |
| EP (3) | EP2808393B1 (enExample) |
| JP (4) | JP5744856B2 (enExample) |
| KR (2) | KR101441437B1 (enExample) |
| CN (1) | CN102459603B (enExample) |
| AU (1) | AU2010256753B2 (enExample) |
| BR (1) | BRPI1010035A2 (enExample) |
| CA (1) | CA2764370C (enExample) |
| DK (3) | DK3279326T3 (enExample) |
| ES (2) | ES2527173T3 (enExample) |
| HU (1) | HUE038596T2 (enExample) |
| IL (1) | IL216624A (enExample) |
| PL (3) | PL2808393T3 (enExample) |
| SG (1) | SG176251A1 (enExample) |
| TW (1) | TWI513818B (enExample) |
| WO (1) | WO2010141478A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140161782A1 (en) | 2008-06-09 | 2014-06-12 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| JP2014509850A (ja) | 2011-03-06 | 2014-04-24 | メルク セロノ ソシエテ アノニム | 低フコース細胞株およびその使用 |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2722673B1 (en) | 2012-10-17 | 2017-07-12 | Hexal AG | Improved method of mapping glycans of glycoproteins |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| WO2015057393A1 (en) * | 2013-10-01 | 2015-04-23 | University Of Wyoming | Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| CN106604930B (zh) * | 2014-05-30 | 2021-10-29 | 新英格兰生物实验室公司 | 去糖基化试剂和方法 |
| US20170121673A1 (en) * | 2014-07-07 | 2017-05-04 | Targazyme, Inc. | Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Use |
| CN105671109B (zh) * | 2014-11-20 | 2019-08-23 | 中国人民解放军军事医学科学院生物工程研究所 | 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| WO2017079165A1 (en) * | 2015-11-02 | 2017-05-11 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| MX2018008447A (es) * | 2016-01-06 | 2019-05-30 | Oncobiologics Inc | Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. |
| CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| SG10202010156XA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| MX2018012868A (es) * | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
| EP3339444A1 (en) * | 2016-12-20 | 2018-06-27 | Mabxience Research, S.L. | Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans |
| CN119639849A (zh) | 2018-03-26 | 2025-03-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| JP7216806B2 (ja) * | 2018-08-29 | 2023-02-01 | ユナイテッド バイオファーマ インコーポレイテッド | アフコシル化抗体およびその製造法 |
| CN113423731B (zh) | 2018-10-29 | 2024-05-14 | 株式会社免疫生物研究所 | 抗hiv抗体及其制造方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| AU2021282179A1 (en) | 2020-05-26 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
| MX2022014852A (es) | 2020-06-03 | 2023-02-01 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2. |
| CN112843234B (zh) * | 2021-01-20 | 2022-09-06 | 四川大学华西第二医院 | 一种调控生物机体内gdp-甘露糖的浓度的装置 |
| AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
| IL309048A (en) | 2021-06-22 | 2024-02-01 | Regeneron Pharma | Anti-EGFRVIII drug antibody conjugates and uses thereof |
| EP4370210A1 (en) | 2021-07-14 | 2024-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| JP2025507790A (ja) | 2022-03-02 | 2025-03-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高力価抗体のための製造プロセス |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1006070A (en) | 1909-05-11 | 1911-10-17 | George Walter Durbrow | Method of and means for extracting micro-organisms and solids from water. |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| JP2001145488A (ja) | 1999-11-19 | 2001-05-29 | Natl Inst Of Advanced Industrial Science & Technology Meti | シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子 |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DK2314686T4 (da) * | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US20020150968A1 (en) | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
| WO2002057423A2 (en) | 2001-01-16 | 2002-07-25 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| KR100585140B1 (ko) | 2004-04-26 | 2006-05-30 | 삼성전자주식회사 | 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법 |
| US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| WO2006133148A2 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| CA2679732A1 (en) | 2007-03-07 | 2008-09-18 | Glycofi, Inc. | Production of glycoproteins with modified fucosylation |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| JP5662149B2 (ja) | 2008-08-13 | 2015-01-28 | 協和発酵キリン株式会社 | 遺伝子組換えプロテインｓ組成物 |
| US8409838B2 (en) * | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| JP2014509850A (ja) | 2011-03-06 | 2014-04-24 | メルク セロノ ソシエテ アノニム | 低フコース細胞株およびその使用 |
-
2010
- 2010-06-01 US US12/791,637 patent/US8409838B2/en active Active
- 2010-06-01 TW TW099117652A patent/TWI513818B/zh not_active IP Right Cessation
- 2010-06-01 ES ES10721096.5T patent/ES2527173T3/es active Active
- 2010-06-01 DK DK17192430.1T patent/DK3279326T3/da active
- 2010-06-01 CA CA2764370A patent/CA2764370C/en active Active
- 2010-06-01 WO PCT/US2010/036914 patent/WO2010141478A1/en not_active Ceased
- 2010-06-01 EP EP14179885.0A patent/EP2808393B1/en active Active
- 2010-06-01 DK DK14179885.0T patent/DK2808393T3/en active
- 2010-06-01 AU AU2010256753A patent/AU2010256753B2/en not_active Ceased
- 2010-06-01 PL PL14179885T patent/PL2808393T3/pl unknown
- 2010-06-01 HU HUE14179885A patent/HUE038596T2/hu unknown
- 2010-06-01 EP EP10721096.5A patent/EP2438171B1/en active Active
- 2010-06-01 DK DK10721096.5T patent/DK2438171T3/en active
- 2010-06-01 PL PL10721096T patent/PL2438171T3/pl unknown
- 2010-06-01 PL PL17192430T patent/PL3279326T3/pl unknown
- 2010-06-01 KR KR1020117031320A patent/KR101441437B1/ko not_active Expired - Fee Related
- 2010-06-01 BR BRPI1010035-0A patent/BRPI1010035A2/pt not_active Application Discontinuation
- 2010-06-01 EP EP17192430.1A patent/EP3279326B1/en active Active
- 2010-06-01 JP JP2012514045A patent/JP5744856B2/ja not_active Expired - Fee Related
- 2010-06-01 ES ES14179885.0T patent/ES2661074T3/es active Active
- 2010-06-01 CN CN2010800294912A patent/CN102459603B/zh not_active Expired - Fee Related
- 2010-06-01 SG SG2011087517A patent/SG176251A1/en unknown
- 2010-06-01 KR KR1020147007025A patent/KR101641526B1/ko not_active Expired - Fee Related
-
2011
- 2011-11-27 IL IL216624A patent/IL216624A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/779,952 patent/US9206455B2/en active Active
-
2014
- 2014-12-12 JP JP2014251541A patent/JP2015051021A/ja not_active Withdrawn
-
2015
- 2015-12-08 US US14/963,178 patent/US9550823B2/en active Active
-
2016
- 2016-03-07 JP JP2016043151A patent/JP6211642B2/ja not_active Expired - Fee Related
- 2016-10-14 JP JP2016202634A patent/JP2017006147A/ja active Pending
- 2016-12-14 US US15/378,670 patent/US10006070B2/en active Active
-
2018
- 2018-05-23 US US15/987,286 patent/US20190024129A1/en not_active Abandoned
-
2019
- 2019-08-30 US US16/556,334 patent/US20200080124A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,255 patent/US11560550B2/en active Active
-
2022
- 2022-12-15 US US18/066,303 patent/US12054751B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004867A (es) | Proceso mejorado para la produccion de oligosacaridos fucosilados. | |
| MX339769B (es) | Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos. | |
| BR112012002137B8 (pt) | método para produzir um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua isenta de soro | |
| CL2011002518A1 (es) | Proceso para producir un vegetal, una semilla o su progenie, basado en transformar células vegetales con una secuencia de ácido nucleico que codifica una proteína quinasa relacionada con snf1, vector que comprende dicha secuencia; y métodos de aplicación. | |
| EA201170638A1 (ru) | Способ получения аденовирусных векторов | |
| MX2018004146A (es) | Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t. | |
| MX389666B (es) | Induccion de celulas pluripotentes. | |
| EP2224921A4 (en) | MODULATION OF THE IMMUNE RESPONSE | |
| BRPI0817299A8 (pt) | vacinas e componentes de vacina para inibição de células microbianas | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| MX2019012311A (es) | Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso. | |
| SG196784A1 (en) | Stem cell cultures | |
| BR112014005352A2 (pt) | organismos eucarióticos e métodos para aumentar a disponibilidade de acetil-coa citosólico e para produzir 1,3-butanodiol | |
| WO2018097540A3 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
| AR094389A1 (es) | USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS | |
| ES2627330T3 (es) | Uso de JAZ5a para mejorar la resistencia a la sequía en una planta | |
| BR112015021993A2 (pt) | composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo | |
| ES2613400T3 (es) | Método para mejorar la fagocitosis de células que exponen fosfatidilserina | |
| ES2337973B8 (es) | Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad. | |
| BR112014019328A8 (pt) | Perfil de fenótipo de células progenitoras retinais humanas | |
| BR112015019156A2 (pt) | cultivo autotrófico | |
| WO2005094353A3 (en) | Methods for production of regulatory t cells and uses thereof | |
| CL2017002661A1 (es) | Método de producción de gonadotrofina | |
| MX336722B (es) | Agentes de imagenologia molecular etiquetados, metodos para hacerlos y metodos de uso. | |
| SA518391430B1 (ar) | خلية كهروكيميائية وعملية |